If you watch television, you've probably come across a commercial for AndroGel, AbbVie's blockbuster prescription gel for treating low testosterone levels. The technical term for the ailment is hypogonadism, and it's a $2 billion market -- and growing. Markets like that don't come without admirers, and in this case one of those is Repros Therapeutics . The company is developing an oral drug for secondary hypogonadism called Androxal, and in the following video Brenton Flynn discusses why its stock soared today.
Is Repros the least of AbbVie's worries?
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking, and as an added bonus, you'll receive a full year of free analyst updates as significant news hits. Simply click here now to claim your copy today.
The article Repros Soars -- and AbbVie Might Suffer originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.